Results 21 to 30 of about 557 (132)

A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. [PDF]

Nat Metab
Abstract Amylin receptor agonists such as cagrilintide represent emerging obesity therapies. To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to ...
Ludwig MQ, Coester B, Gordian D, Hassan S, Tomlinson AJ, Toure MH, Christensen OP, Lommi G, Moltke-Prehn A, Brown JM, Belmont-Rausch DM, Bau S, Bodur C, Gowda A, Wu I, Kernodle S, Dong V, Ayensu-Mensah M, Sabatini PV, Shin JH, Kirigiti M, Egerod KL, Le Foll C, Lundh S, Gerstenberg MK, Lutz TA, Kievit P, Secher A, Raun K, Myers MG, Pers TH.   +30 more
europepmc   +2 more sources

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity [PDF]

Journal of Obesity & Metabolic Syndrome
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj   +2 more sources

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept [PDF]

Molecular Metabolism
Objectives: Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.
Daniel A. Briere, Hongchang Qu, Katherine Lansu, Minxia Michelle He, Julie S. Moyers, Tamer Coskun, Annie Long, Dawn Allen, Libbey O'Farrell, Breanna Bowen, Edward Pratt, Beth Tidemann-Miller, Lai San Tham, Hilda Ibriga, Jorge Alsina-Fernandez, Kieren J. Mather, Axel Haupt, Shobha N. Bhattachar   +17 more
doaj   +2 more sources

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications [PDF]

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Zachary Bloomgarden
wiley   +2 more sources

Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials [PDF]

Diabetes, Metabolic Syndrome and Obesity
Chuhan Shao, Hanmo Lin, Jie Yu, Haiyan Chen, Yaolin Ren, Jing Ren, Yuan Zeng, Yifan Wu, Haoyu Bai, Qian Zhang, Xinhua XiaoNHC Key Laboratory of Endocrinology (Peking Union Medical College Hospital), Diabetes Research Center of Chinese Academy of Medical ...
Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, Zeng Y, Wu Y, Bai H, Zhang Q, Xiao X   +10 more
doaj   +2 more sources

Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes [PDF]

Metabolism Open
Introduction: Amylin-pathway therapies represent a novel therapeutic class for obesity and type 2 diabetes, however head-to-head comparative data and long-term outcome predictions remain limited.
Faisal A. Al-Harbi, Ahmed K. Alsaif, Atheer G. Almutairi, Hussam J. Alshehri, Elan A. Aleidan, Ghaida S. Alabdulaaly, Mashael E. Alanazi, Ahmed Y. Azzam   +7 more
doaj   +2 more sources

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies [PDF]

Metabolism Open
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Ioannis G. Lempesis, Maria Dalamaga
doaj   +2 more sources

The Evolution of Medications for Obesity Management [PDF]

JGH Open, Volume 10, Issue 9, September 2026.
ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns.
Jaskirath Gill, Priya Sumithran
wiley   +2 more sources

Effects of Incretin‐Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat‐Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis [PDF]

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7737-7751, September 2026.
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Laura Busk‐Cirera, Ida Ørum Carlsen, Lærke Bruun Madsen, Rasmus Michael Sandsdal, Emma Jensen, Simon Birk Kjær Jensen, Signe Sørensen Torekov   +6 more
wiley   +2 more sources

The Overlooked Role of Psychiatrists in Obesity Management: A Multidisciplinary Perspective [PDF]

Eur Psychiatry
Introduction Obesity is a chronic, multifactorial condition often associated with psychiatric comorbidities and a significant stigma burden.
Dos Santos D, Castanheira da Silva A, Miranda F.   +2 more
europepmc   +2 more sources